ArticleJACC. Advances2026
Lipoprotein(a) in Disaggregated South Asian Groups: An Analysis of MASALA and the UK Biobank.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundSouth Asian individuals have a high prevalence of elevated lipoprotein(a) [Lp(a)], but little is known about the variation between disaggregated South Asian subgroups.
objectivesThe authors aimed to evaluate Lp(a) levels, nongenetic influences, and the association with incident atherosclerotic cardiovascular disease (ASCVD) in South Asian populations using data from the Meditators of Atherosclerosis in South Asians Living in America (MASALA) and the UK Biobank (UKB) studies.
methodsLp(a) levels were assessed by South Asian country of origin and by state among Indian-origin participants. The association between nongenetic factors and Lp(a) levels was evaluated in multivariable linear regression models. Cox proportional hazards models evaluated the association between Lp(a) and ASCVD events in UKB participants.
resultsAmong 2,074 MASALA participants born in the South Asian subcontinent (mean age: 56.7 ± 9.6 years), median [Q1-Q3] Lp(a) was 20.7 [10.5-43.0] mg/dL with significant variation by country of origin (P = 0.035). Median Lp(a) was 23 [11-48], 19 [10-37], 22 [11-47], and 17 [10-34] mg/dL in participants from Bangladesh, India, Pakistan, and Sri Lanka, respectively. Vegetarian diet, statin use, postmenopausal status, and fewer years in the United States were associated with higher Lp(a) levels while alcohol consumption was associated with lower Lp(a) levels. However, these associations were all very modest. Among 6,845 UKB participants (mean age: 55.1 ± 8.7 years; median Lp(a): 31 [13-65] nmol/L), the associations between Lp(a) and ASCVD did not vary by country of origin or South Asian ethnicity (P interaction > 0.05).
conclusionsThere is modest variation in Lp(a) levels, but no difference in the association between Lp(a) and ASCVD outcomes, across South Asian subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.